Clinical Efficacy of Dendritic Cell Cytokine-Induced Killer Cells Combined with Chemotherapy for Patients with Gastroenteric Tumor
-
摘要:
目的 分析比较DC-CIK联合化疗治疗胃肠道肿瘤与疗效相关的参数，评估以DC-CIK为基础免疫治疗胃肠道肿瘤的有效性和安全性。 方法 选取2008年10月至2011年10月山西省肿瘤医院生物治疗科58例DC-CIK细胞治疗联合化疗的进展期胃肠道肿瘤患者，同期临床特点相近的病例68例作为对照组接受单纯化疗，比较两组患者治疗后患者细胞免疫功能、近期疗效、生存质量等，并观察DC-CIK细胞治疗的安全性。 结果 DC-CIK联合治疗组患者CD8+、NKT细胞治疗后细胞百分比明显提高，与对照组相比CD3+、CD8+、NKT细胞百分比均提高，差异有统计学意义（P < 0.05）；Th1/Th2细胞胞内细胞因子同治疗前和同期对照组治疗后相比较，Th1细胞胞内细胞因子IFN-γ、IL-2、TNF-α表达升高，差异有统计学意义（P < 0.05）；两组患者近期疗效观察，DC-CIK联合治疗组DCR 75.9 %，与对照组（58.8%）相比较有所提高（P < 0.05）；DC-CIK联合治疗组患者生存质量较对照组有不同程度的提高。 结论 与单纯化疗相比，以DC-CIK为基础的过继性细胞免疫治疗安全、有效，可提高缓解率，改善患者生存质量。 Abstract:Objective To analyze and compare the curative effect-related parameters of dendritic cell cytokine-induced killer cells (DC - CIK) biotherapy combined with chemotherapy in treating patients with gastrointestinal tumors. The safety and therapeutic effectiveness of DC-CIK were evaluated. Methods Fifty-eight patients with gastroenteric tumor admitted to the Shanxi Provincial Cancer Hospital from October 2008 to October 2011 were treated with the regimen of DC-CIK-based immunotherapy combined with chemotherapy. Another 68 patients with advanced gastrointestinal tumor treated with chemotherapy alone during the same period were taken as controls. The immune function, therapeutic effect, quality of life, and side effects were compared between the two groups. The safety and therapeutic effects of DC-CIK therapy were observed. Results In the group of DC-CIK and chemotherapy, the ratios of CD3+, CD8+, and NKT cells were significantly higher than that of the control group (P < 0.05). The level of Th1 cytokines (IFN - r, IL - 2, TNF - a) was significantly increased compared with Th1 / Th2 cytokines (P < 0.05). For short-term curative effect, disease control rate was higher in the group of DC-CIK combined with chemotherapy than in the control group (75.9 % vs. 58.8 %, P < 0.05). Life quality was more improved in the group of DC-CIK combined with chemotherapy compared with controls. Conclusion The combined regimen of DC-CIK with chemotherapy in treating gastroenteric tumor patients is safe and effective and can improve the remission rate and the quality of life. -
Key words:
- DC-CIK /
- Adoptive cellular immunotherapy /
- Gastroenteric tumor /
- Cellular immune function
-
表 1 126例胃肠道肿瘤患者一般资料
例 Table 1. Characteristics of patients
表 2 DC-CIK治疗的适应症和禁忌症
Table 2. Indications and contraindications of DC-CIK immunotherapy
表 3 化疗+DC-CIK组和单纯化疗组患者外周血T细胞亚群的变化
x±s，% Table 3. Changes in T cell subsets in peripheral blood of chemotherapy plus DC-CIK group and chemotherapy group
(x±s, %) 
表 4 化疗+DC-CIK组和单纯化疗组患者外周血Th1/Th2细胞胞内细胞因子的变化
x±s，% Table 4. Changes in Th1/Th2 cells in peripheral blood of chemotherapy plus DC-CIK group and chemotherapy group
(x±s, %) 
表 5 化疗+DC-CIK组和单纯化疗组患者疗效比较
例 Table 5. Comparison of therapeutic effect between chemotherapy plus DC-CIK and simple chemotherapy
n 
表 6 化疗+DC-CIK组与单纯化疗组患者治疗前后的生存质量评价
% Table 6. Quality of life of patients receiving chemotherapy plus DC-CIK or chemotherapy alone
% 
-
[1] Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010[J]. CA Cancer J Clin, 2010, 60(5): 277-300. doi: 10.3322/caac.20073 [2] Karlsson M, Marits P, Dahl K, et al. Pilot study of sentinel node-based adoptive immunotherapy in advanced colorectal cancer[J]. Ann Surg Oncol, 2010, 17(7): 1747-1757. doi: 10.1245/s10434-010-0920-8 [3] Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world[J]. J Clin Oncol, 2006, 24(14): 2137-2150. doi: 10.1200/JCO.2005.05.2308 [4] Corley DA, Buffler PA. Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in Five Continents database[J]. Int J Epidemiol, 2001, 30(6): 1415-1425. doi: 10.1093/ije/30.6.1415 [5] Rosenberg SA, Restifo NP, Yang JC, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy[J]. Nat Rev Cancer, 2008, 8(4): 299-308. doi: 10.1038/nrc2355 [6] Lopez RD, Waller EK, Lu PH, et al. CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56+ T cells[J]. Cancer Immunol Immunother, 2001, 49(12): 629-640. doi: 10.1007/s002620000148 [7] 张俊萍, 毛光华, 史天良, 等. DC-CIK联合化疗治疗晚期非小细胞肺癌的临床疗效[J]. 中国肿瘤生物治疗杂志, 2011, 18(4): 424-429. doi: 10.3872/j.issn.1007-385X.2011.04.016 [8] Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Rearch and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trail in oncology[J]. J Natl Cancer Inst, 1993, 85(5): 356-376. [9] 姜宝法, 刘春晓, 崔永春, 等. EORTC QLQ-C30的信都、教都研究[J]. 中国临床心理学杂志, 2005, 13(1): 31-32. doi: 10.3969/j.issn.1005-3611.2005.01.009 [10] Linn YC, Lau SKJ, Liu BH, et al. Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell[J]. Immunology, 2009, 126(3): 423-435. doi: 10.1111/j.1365-2567.2008.02910.x [11] Alajez NM, Schmielau J, Alter MD, et al. Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on eff ector cells of the innate and the adaptive immune systemthrough bonemarrow transduction and immune reconstitution[J]. Blood, 2005, 105 (12): 4583-4589. doi: 10.1182/blood-2004-10-3848 [12] Barnd DL, Lan MS, Metzgar RS, et al. Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells[J]. Proc Natl Acad Sci U S A, 1989, 86(18): 7159-7163. doi: 10.1073/pnas.86.18.7159 [13] Magarian-Blander J, Ciborowski P, Hsia S, et al. Intercellular and intracellular events following the MHC-unrestricted TCR recognition of a tumor-specific peptide epitope on the epithelial antigen MUC1[J]. Journal of Immunology, 1998, 160(7): 3111-3120. http://www.europepmc.org/abstract/MED/9531265 [14] Sabado RL, Bhardwaj N. Directing dendritic cell immunotherapy towards successful cancer treatment[J]. Immunotherapy, 2010, 2(1): 37-56. doi: 10.2217/imt.09.43 [15] Ilett EJ, Prestwich RJ, Melcher AA. The evolving role of dendritic cells in cancer therapy[J]. Expert Opin Biol Ther, 2010, 10(3): 369-379. doi: 10.1517/14712590903559830 [16] Osada T, Clay T, Hobeika A, et al. NK cell activati on by dendritic cell vaccine: a mechanism of action for clinical activity[J]. Cancer Immunol Immunother, 2005, 55(9): 1122-1131. http://www.onacademic.com/detail/journal_1000034448472210_dba0.html [17] Finn OJ. Cancer Immunology[J]. N Engl J Med, 2008, 358(25): 2704-2715. doi: 10.1056/NEJMra072739 [18] Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion[J]. Nat Rev Immunol, 2006, 6(10): 715-727. doi: 10.1038/nri1936 [19] Nagorsen D, Scheibenbogen C, Marincola FM, et al. Natural T cell immunity against cancer[J]. Clin Cancer Res, 2003, 9(12): 4296-4303. [20] Wheeler CJ, Black KL, Liu G, et al. Vaccination elicits correlated immune an dclinical responses in glioblastoma multiforme patients[J]. Cancer Res, 2008, 68(14): 5955-5964. doi: 10.1158/0008-5472.CAN-07-5973 [21] 巩新建, 刘军全, 李玺, 等. 进展期胃癌术后自身CIK细胞和树突状细胞联合治疗的临床观察[J]. 中国肿瘤临床, 2007, 34(14): 803-806. doi: 10.3969/j.issn.1000-8179.2007.14.006 [22] Hontscha C, Borck Y, Zhou H, et al. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC)[J]. J Cancer Res Clin Oncol, 2011, 137(2): 305-310. doi: 10.1007/s00432-010-0887-7 -
点击查看大图
表(6)
计量
- 文章访问数: 28
- HTML全文浏览量: 2
- PDF下载量: 1
- 被引次数: 0
下载:
